Journal of Oncology Pharmacy Practice This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Galectin-3 and matrix metalloproteinase-9: Perspective in management of hepatocellular carcinoma
Conclusion MMP-9 and galectin-3 could be used as a guide for prognosis of HCC since they may play a role in HCC progression and metastasis. However, they are not useful markers for HCC diagnosis. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - August 25, 2015 Category: Cancer & Oncology Authors: Eisa, N. H., Ebrahim, M. A., Ragab, M., Eissa, L. A., El-gayar, A. M. Tags: Original Articles Source Type: research

Reply To the Editor, Re: Bicakli et al. Adjuvant chemotherapy may contribute to an increased risk for metabolic syndrome in patients with breast cancer. J Oncol Pharm Pract, published online September 2014. DOI: 10.1177/1078155214551315
(Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - June 29, 2015 Category: Cancer & Oncology Authors: Bicakli, D. H., Varol, U., Degirmenci, M., Tunali, D., Cakar, B., Durusoy, R., Karaca, B., Sanli, U. A., Uslu, R. Tags: Letters to the Editor Source Type: research

Re: Bicakli et al. Adjuvant chemotherapy may contribute to an increased risk for metabolic syndrome in patients with breast cancer. J Oncol Pharm Pract, published online September 2014. DOI: 10.1177/1078155214551315
(Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - June 29, 2015 Category: Cancer & Oncology Authors: Agilli, M., Aydin, F. N. Tags: Letters to the Editor Source Type: research

Carfilzomib-related acute kidney injury may be prevented by N-acetyl-L-cysteine
We describe a case of a 78-year-old man with refractory multiple myeloma with acute kidney injury associated with carfilzomib treatment. We show that use of N-acetyl-l-cysteine in our patient partially mitigated the renal injury upon re-challenge. This case report hypothesizes that acute renal injury from carfilzomib is caused by vasoconstriction of the renal vessels, which may be prevented by N-acetyl-l-cysteine. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - June 29, 2015 Category: Cancer & Oncology Authors: Wanchoo, R., Khan, S., Kolitz, J. E., Jhaveri, K. D. Tags: Case Reports Source Type: research

The combination of weekly trastuzumab plus vinorelbine may be preferable regimen in HER-2 positive breast cancer patients with brain metastasis
Brain metastasis is one of the most important life-threatening conditions in patients with metastatic HER-2 positive breast cancer. A lot of conventional chemotherapeutic and antibody-based regimens used routinely in treatment of the patients with breast cancer are not effective due to blood–brain barrier. In our cases, we reported on three HER-2 positive breast cancer patients with brain metastasis who were offered a combination of weekly trastuzumab plus vinorelbine after brain metastasis. In our cases, the progression-free survival were 12, 16 and 9 months for Case 1, Case 2 and Case 3, respectively. In Case 1, th...
Source: Journal of Oncology Pharmacy Practice - June 29, 2015 Category: Cancer & Oncology Authors: Mutlu, H., Buyukcelik, A. Tags: Case Reports Source Type: research

A case series using famciclovir in stem cell transplant recipients with valacyclovir hypersensitivity reactions
Conclusion Due to the limited data available, famciclovir appears to be a reasonable option in immunocompromised patients with a mild valacyclovir or acyclovir hypersensitivity reaction. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - June 29, 2015 Category: Cancer & Oncology Authors: Shah, S. A., Gulbis, A., Wilhelm, K. Tags: Case Reports Source Type: research

Severe pegfilgrastim-induced bone pain completely alleviated with loratadine: A case report
We present the first case report in which loratadine prophylaxis completely alleviated NSAID-resistant severe pain secondary to pegfilgrastim. The result showed that loratadine may be a promising option for severe, resistant pegfilgrastim-induced bone pain. Further clinical studies are warranted and ongoing. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - June 29, 2015 Category: Cancer & Oncology Authors: Romeo, C., Li, Q., Copeland, L. Tags: Case Reports Source Type: research

Nelarabine neurotoxicity with concurrent intrathecal chemotherapy: Case report and review of literature
Severe nelarabine neurotoxicity in a patient who received concurrent intrathecal (IT) chemotherapy is reported. A 37-year-old Caucasian woman with a history of T-cell lymphoblastic lymphoma was admitted for relapsed disease. She was originally treated with induction chemotherapy followed by an autologous transplant. She developed relapsed disease 10 months later with leukemic involvement. She was re-induced with nelarabine 1500 mg/m2 on days 1, 3, and 5 with 1 dose of IT cytarabine 100 mg on day 2 as central nervous system (CNS) prophylaxis. At the time of treatment, she was on continuous renal replacement therapy due to s...
Source: Journal of Oncology Pharmacy Practice - June 29, 2015 Category: Cancer & Oncology Authors: Ngo, D., Patel, S., Kim, E. J., Brar, R., Koontz, M. Z. Tags: Case Reports Source Type: research

Facing the challenges of new melanoma-targeted therapies: Treatment of severe fevers associated with dabrafenib/trametinib combination therapy
We report a patient who was debilitated by severe pyrexia and rigors caused by dabrafenib used in combination with trametinib to treat metastatic melanoma, who was treated with low-dose steroids. To our knowledge, the use of prednisolone for the treatment and prevention of further dabrafenib-associated pyrexia is not published; however, it is a low risk and low cost option that was very effective in this case. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - June 29, 2015 Category: Cancer & Oncology Authors: Lindsay, J. N., Barras, M. Tags: Case Reports Source Type: research

Tolerability of Velcade (Bortezomib) subcutaneous administration using a maximum volume of 3 mL per injection site
Subcutaneous injection is now commonly used as a standard for bortezomib administration. The bortezomib (Velcade®) product monograph recommends that intravenous injections be prepared at a concentration of 1 mg/mL, while subcutaneous injections may be prepared at a concentration of 2.5 mg/mL. Many institutions and subcutaneous administration guidelines use 2 mL as the maximum volume for subcutaneous injection. Using 2 mL as the maximum volume for injection would mean that many patients receiving bortezomib will receive two injections during each visit with common dosing parameters. In this prospective study evaluating ...
Source: Journal of Oncology Pharmacy Practice - June 29, 2015 Category: Cancer & Oncology Authors: Ng, P., Incekol, D., Lee, R., Paisley, E., Dara, C., Brandle, I., Kaufman, M., Chen, C., Trudel, S., Tiedemann, R., Reece, D., Kukreti, V. Tags: Original Articles Source Type: research

Potential cost savings associated with dose rounding antineoplastic monoclonal agents
Conclusion Consultation with key physicians regarding the proposed percent reduction resulted in a 10% dose reduction for all cases when utilizing these three agents. Implementation of a dose rounding protocol for bevacizumab, trastuzumab, and cetuximab represents a potentially substantial cost savings at this institution. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - June 29, 2015 Category: Cancer & Oncology Authors: Francis, S. M., Heyliger, A., Miyares, M. A., Viera, M. Tags: Original Articles Source Type: research

Evaluating the effectiveness and safety of hydrocortisone therapy in cancer patients with septic shock
Conclusions HC therapy was associated with resolution of septic shock in about half of the patients and a high incidence of secondary infections. Prospective studies are needed to fully assess the efficacy and safety of HC in cancer patients with septic shock. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - June 29, 2015 Category: Cancer & Oncology Authors: Nazer, L., AlNajjar, T., Al-Shaer, M., Rimawi, D., Hawari, F. Tags: Original Articles Source Type: research

Testing the degradation effects of three reagents on various antineoplastic compounds
Conclusion Although three of four antineoplastic compounds were degraded successfully, any combinations of three reagents could not degrade cyclophosphamide completely. However, the addition of sodium thiosulfate which inhibits the corrosion of metal by sodium hypochlorite is essential for daily cleaning. Therefore, the evaluation of reaction time before the addition of sodium thiosulfate may be required. We will continue to investigate the reagents for degradation. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - June 29, 2015 Category: Cancer & Oncology Authors: Gohma, H., Inoue, Y., Asano, M., Sugiura, S.-I. Tags: Original Articles Source Type: research

Claims analysis of hypertension occurrence, severity changes and patterns of antihypertensive use in cancer patients receiving vascular endothelial growth factor inhibitors
Conclusion Our study provides valuable insight into non-trial patterns of vascular endothelial growth factor inhibitor-associated hypertension occurrence and severity, and is consistent with prior claims analysis. Identification of optimal strategies to manage vascular endothelial growth factor inhibitor-associated hypertension remain to be clarified with the advent of more comprehensive data sets. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - June 29, 2015 Category: Cancer & Oncology Authors: Thompson, L. A., Saseen, J. J., O'Bryant, C. L., Allen, R. R., Nair, K. V. Tags: Original Articles Source Type: research

Oral chemotherapy practices at Ontario cancer centres
Conclusion Results indicate a lack of formal policies and variable practices across all aspects of oral chemotherapy in many regions. However, some regions have developed and implemented successful initiatives. The results from this review are informing provincial priorities and being shared between regions to support collaborative learning. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - June 29, 2015 Category: Cancer & Oncology Authors: Ahmad, N., Simanovski, V., Hertz, S., Klaric, G., Kaizer, L., Krzyzanowska, M. K. Tags: Original Articles Source Type: research